Artivion (NYSE:AORT – Get Free Report) is set to post its quarterly earnings results after the market closes on Thursday, November 7th. Analysts expect Artivion to post earnings of $0.03 per share for the quarter. Artivion has set its FY 2024 guidance at EPS.Investors that wish to register for the company’s conference call can do so using this link.
Artivion (NYSE:AORT – Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.04. Artivion had a negative net margin of 2.22% and a positive return on equity of 3.81%. The company had revenue of $98.02 million for the quarter, compared to analysts’ expectations of $97.70 million. On average, analysts expect Artivion to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Artivion Price Performance
Shares of AORT opened at $26.64 on Thursday. The firm has a 50-day simple moving average of $25.96 and a two-hundred day simple moving average of $24.76. The stock has a market cap of $1.12 billion, a PE ratio of -127.95 and a beta of 1.74. Artivion has a 1-year low of $12.47 and a 1-year high of $29.24. The company has a debt-to-equity ratio of 1.07, a current ratio of 5.63 and a quick ratio of 4.04.
Wall Street Analyst Weigh In
Check Out Our Latest Report on AORT
Insider Transactions at Artivion
In related news, CAO Amy Horton sold 12,430 shares of the stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total value of $325,417.40. Following the transaction, the chief accounting officer now owns 139,989 shares of the company’s stock, valued at $3,664,912.02. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, SVP Jean F. Holloway sold 3,167 shares of the company’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $26.55, for a total value of $84,083.85. Following the completion of the sale, the senior vice president now directly owns 161,932 shares of the company’s stock, valued at $4,299,294.60. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Amy Horton sold 12,430 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total value of $325,417.40. Following the transaction, the chief accounting officer now owns 139,989 shares in the company, valued at $3,664,912.02. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 37,109 shares of company stock valued at $951,935. 8.10% of the stock is currently owned by corporate insiders.
About Artivion
Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.
Featured Articles
- Five stocks we like better than Artivion
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- What is a Bond Market Holiday? How to Invest and Trade
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- 3 Monster Growth Stocks to Buy Now
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.